Imagine having a digital copy of your own heart and circulatory system that doctors can test treatments on before giving them to you. It uses data from your clinic visits and smartwatches to predict how your body will react to a specific drug or surgery. This helps doctors pick the best treatment for your specific body and gender without the guesswork.
Current cardiovascular care often relies on general guidelines rather than individual patient biology, leading to trial-and-error in drug dosing and surgical interventions for complex heart failure and hypertension.
A multi-scale, multi-organ modelling platform that creates virtual human twins using clinical and wearable data to optimize medical and surgical therapies.
If you are a drug developer dealing with high failure rates in cardiovascular clinical trials — this project developed a multi-scale modelling platform that allows for sex-specific optimization of pharmacological therapy. This enables more precise patient selection and predicted outcomes for heart failure and hypertension.
If you are a wearable tech manufacturer dealing with data that lacks clinical utility — this project developed a platform that integrates wearable technology data into a virtual human twin. This transforms raw sensor data into actionable clinical insights for managing complex cardiovascular disorders.
If you are a clinic dealing with patients who have resistant systemic hypertension or heart failure — this project developed user-friendly interfaces for virtual twins that predict disease progression over months to years. This allows for more cost-effective patient management strategies.
Based on available project data, no pricing or cost structures have been disclosed as the project is currently in the research and validation phase.
The project is designed for clinical scale, with validation planned across 5 clinical studies and over 200 patients in France and the UK.
Based on available project data, specific licensing terms are not mentioned, but the technology is designed to be compliant with the VPHi and EDITH virtual twin ecosystems.
The platform focuses on ethical and legal challenges of digital health and is designed to be compliant with EU initiatives for virtual human twins.
The project period runs from 2024-01-01 to 2028-12-31, suggesting the platform will be fully validated by the end of 2028.
The consortium is heavily research-driven with 9 universities and 3 research institutes, but includes 2 industry partners (14% ratio). This structure indicates a high-tech development focus with a lean commercialization bridge, leveraging expertise across 10 countries including the UK, France, and Belgium.
Contact Universiteit Gent regarding the VITAL multi-scale modelling platform.
Contact us to explore licensing opportunities for virtual twin cardiovascular models.
